Treatment patterns and survival of individuals with early stage non-small cell lung cancer in Germany - a study based on cancer registry data (I-O OPTIMISE / VONKO-019)

Treatment patterns and survival of individuals with early stage non-small cell lung cancer in Germany - a study based on cancer registry data (I-O OPTIMISE / VONKO-019) - VONKOdb Early stage NSCLC 2023

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033794

Enrollment

70000

Registered

2024-03-01

Start date

2024-03-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34

Interventions

Group 1: Retrospective analysis of patients with early stage NSCLC diagnosed in 2016-2019

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: - diagnosis years 2016-2019 - place of residence in respective federal state of cancer registry

Exclusion criteria

Exclusion criteria: patient is known to the cancer registry only by means of death certificate, a pathology report, a follow up notification, a tumor conference report or a combination of the aforementioned

Design outcomes

Primary

Measure	Time frame
Treatment patterns in patients with early stage non-small cell lung tumor (LAM NSCLC) - from the time of diagnosis to the end of follow-up (i) Description of the sequence of therapy options surgery, radiation, systemic anticancer therapy (chemotherapy, immunotherapy). (ii) Classification of systemic anticancer therapy into lines of therapy according to the treatment guidelines for NSCLC. For this purpose, the cancer registry data are used, which are recorded in a standardized form. For the scope and type of data collected, see the data set description in the Federal Gazette (Bundesanzeiger) 2021: BAnz AT 12.07.2021 B4	—

Measure

Time frame

Treatment patterns in patients with early stage non-small cell lung tumor (LAM NSCLC) - from the time of diagnosis to the end of follow-up (i) Description of the sequence of therapy options surgery, radiation, systemic anticancer therapy (chemotherapy, immunotherapy). (ii) Classification of systemic anticancer therapy into lines of therapy according to the treatment guidelines for NSCLC. For this purpose, the cancer registry data are used, which are recorded in a standardized form. For the scope and type of data collected, see the data set description in the Federal Gazette (Bundesanzeiger) 2021: BAnz AT 12.07.2021 B4

—

Secondary

Measure	Time frame
Overall survival (a) from diagnosis to end of observation/ follow-up (=death or censoring [vital status alive at last linkage to registration offices in spring2022]).	—

Countries

Germany

Contacts

Public ContactAnnika Waldmann

Universität zu Lübeck, Institut für Sozialmedizin und Epidemiologie

Annika.Waldmann@uksh.de+49 4510 50051201

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026